Literature DB >> 16409557

SUMOylation substrates in neuronal intranuclear inclusion disease.

J Takahashi-Fujigasaki1, K Arai, N Funata, H Fujigasaki.   

Abstract

Neuronal intranuclear inclusion disease (NIID) is a rare neurodegenerative disorder characterized pathologically by the presence of ubiquitinated intranuclear inclusions (NII) in neuronal cells. We demonstrate that NIIs in both sporadic and familial NIID contained the small ubiquitin modifier-1 (SUMO-1) and the SUMOylation substrates promyelocytic leukaemia protein (PML) and histone deacetylase 4 (HDAC4). Both PML and SUMO-1 are major components of nuclear bodies (NBs), suggesting that the NIIs in NIID, as well as the intranuclear inclusions in polyglutamine diseases, might derive from these intranuclear functional domains that serve as sites for ubiquitin-related protein degradation. HDAC4 was also a major component of the NIIs. HDACs are transcriptional corepressors that regulate histone remodelling, and NBs are thought to be sites at which the level of histone acetylation is controlled. The presence of PML, SUMO-1 and HDAC4 in NIIs suggests that transcriptional activity regulated by histone acetylation might contribute to the disease process in NIID. In addition, we showed that another SUMOylation substrate, RanGAP1 is associated with NIIs only in the familial NIID patient. This might be explained by different pathogenetic mechanisms underlying subcategories of NIID, which is very heterogeneous.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409557     DOI: 10.1111/j.1365-2990.2005.00705.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  17 in total

1.  A case of recurrent vomiting: extending the spectrum of neuronal intranuclear inclusion disease.

Authors:  Xiaoyun Liu; Xiaohui Liu; Yifeng Du; Youting Lin; Chunxia Li; Cuicui Liu; Lin Lu
Journal:  Neurol Sci       Date:  2019-07-02       Impact factor: 3.307

2.  Optineurin immunoreactivity in neuronal and glial intranuclear inclusions in adult-onset neuronal intranuclear inclusion disease.

Authors:  Masataka Nakamura; Melissa E Murray; Wen-Lang Lin; Hirofumi Kusaka; Dennis W Dickson
Journal:  Am J Neurodegener Dis       Date:  2014-09-06

3.  Neuronal Intranuclear Inclusion Disease: Longitudinal Case Report of Motor and Nonmotor Symptoms.

Authors:  Jennifer Vermilion; Mahlon Johnson; Jayasri Srinivasan; Jonathan W Mink
Journal:  J Child Neurol       Date:  2019-07-15       Impact factor: 1.987

Review 4.  Class IIA HDACs in the regulation of neurodegeneration.

Authors:  Nazanin Majdzadeh; Brad E Morrison; Santosh R D'Mello
Journal:  Front Biosci       Date:  2008-01-01

Review 5.  Sumoylation in neurodegenerative diseases.

Authors:  Petranka Krumova; Jochen H Weishaupt
Journal:  Cell Mol Life Sci       Date:  2012-09-25       Impact factor: 9.261

Review 6.  Targets and consequences of protein SUMOylation in neurons.

Authors:  Kevin A Wilkinson; Yasuko Nakamura; Jeremy M Henley
Journal:  Brain Res Rev       Date:  2010-04-09

7.  Puromycin-based vectors promote a ROS-dependent recruitment of PML to nuclear inclusions enriched with HSP70 and Proteasomes.

Authors:  Diarmuid M Moran; Hong Shen; Carl G Maki
Journal:  BMC Cell Biol       Date:  2009-05-01       Impact factor: 4.241

Review 8.  Protein SUMOylation in neuropathological conditions.

Authors:  Dina B Anderson; Kevin A Wilkinson; Jeremy M Henley
Journal:  Drug News Perspect       Date:  2009-06

Review 9.  Emerging extranuclear roles of protein SUMOylation in neuronal function and dysfunction.

Authors:  Stéphane Martin; Kevin A Wilkinson; Atsushi Nishimune; Jeremy M Henley
Journal:  Nat Rev Neurosci       Date:  2007-12       Impact factor: 34.870

10.  SUMOylation of DISC1: a potential role in neural progenitor proliferation in the developing cortex.

Authors:  Stephanie Tankou; Kazuhiro Ishii; Christina Elliott; Krishna C Yalla; Jon P Day; Keiko Furukori; Ken-Ichiro Kubo; Nicholas J Brandon; Qiyi Tang; Gary Hayward; Kazunori Nakajima; Miles D Houslay; Atsushi Kamiya; George Baillie; Koko Ishizuka; Akira Sawa
Journal:  Mol Neuropsychiatry       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.